Verastem Oncology
在场
Verastem Oncology 是一家在股票代码 VSTM (US) 下上市的公司。
高管
查看带有其 29 名主要高管的组织结构图
Verastem Oncology 搜索最多的简介
- Dan Paterson, President and Chief Executive Officer
- Brian Stuglik, Director
- Michael Kauffman, Lead Director
高管在Verastem Oncology变化
- Matthew Ros已作为Chief Operating Officer加入公司 (新闻发布的2025一月15号).
创建提醒
跟踪 Verastem Oncology 的高管变动
生物技术
Verastem Oncology 拥有 2,345 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Genus (联合王国)。
Popular M&A news in 生物技术
- Latigo Biotherapeutics 刚刚宣布为 150 筹款数百万美元。 (公布2025三月24号).
- AlloVir and Kalaris Therapeutics have announced they will merge (公布2025三月24号)..
- Purespring Therapeutics 刚刚宣布为 105 筹款数百万美元。 (公布2025三月14号).
生物技术 行业的其他推荐联系人
消息
Verastem Oncology 的最新新闻稿
- Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer | Verastem, Inc.
- Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference | Verastem, Inc.
- Press Releases | Verastem, Inc.
- Press Releases | Verastem, Inc.
- Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates | Verastem, Inc.
- Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer | Verastem, Inc.
- Press Releases | Verastem, Inc.
- Verastem Oncology to Participate in Upcoming Investor Conferences | Verastem, Inc.
- Press Releases | Verastem, Inc.
- Press Releases | Verastem, Inc.
- View more press releases Close
